Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hayward, California 94545


Purpose:

RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer). PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.


Study summary:

OBJECTIVES: Primary - Compare the overall survival of patients with advanced renal cell carcinoma treated with interferon alfa-2b alone or interferon alfa-2b with bevacizumab. Secondary - Compare the time to disease progression and objective response rates in patients treated with these regimens. - Determine the toxicity of interferon alfa-2b in combination with bevacizumab in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior nephrectomy (yes vs no) and number of risk factors for disease progression (0 vs 1-2 vs 3 or more). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive interferon alfa-2b subcutaneously (SC) three times a week. - Arm II: Patients receive interferon alfa-2b as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then annually for up to 10 years after study entry. PROJECTED ACCRUAL: A total of 700 patients (350 per treatment arm) will be accrued for this study within 3 years.


Criteria:

DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed renal cell carcinoma (RCC) - Conventional clear cell carcinoma - Metastatic or unresectable disease - The following characteristics and cellular types are excluded: - True papillary - Sarcomatoid features without a clear cell component - Chromophobe - Oncocytoma - Collecting duct tumor - Transitional cell carcinoma - Measurable or nonmeasurable disease, including any of the following: - Unidimensionally measurable lesion ≥ 20 mm by conventional techniques (e.g., physical exam or chest x-ray) OR 10 mm by spiral CT scan or MRI - The following are considered nonmeasurable disease: - Small lesions - Bone lesions - Leptomeningeal disease - Ascites - Pleural/pericardial effusion - Lymphangitis cutis/pulmonis - Abdominal masses that are not confirmed and followed by imaging techniques - Cystic lesions - Irradiated lesions, unless progression is documented after radiotherapy - RCC paraffin tissue blocks or unstained slides must be available - No evidence of prior or concurrent CNS metastases by MRI or CT scan PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - Granulocyte count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - No history of clinically significant bleeding Hepatic - AST/ALT ≤ 2.5 times upper limit of normal (ULN) - Alkaline phosphatase ≤ 2.5 times ULN - Bilirubin ≤ 1.5 times ULN Renal - Creatinine ≤ 1.5 times ULN - No proteinuria > 1+ - Proteinuria ≥ 2+ allowed provided protein is < 2 g/24-hour urine collection Cardiovascular - No deep venous thrombosis within the past year - No cerebrovascular accident within the past year - No peripheral vascular disease with claudication on < 1 block - No uncontrolled hypertension defined as blood pressure ≥160 mm Hg (systolic) and/or ≥ 90 mm Hg (diastolic) while on medication - No New York Heart Association class II-IV congestive heart failure - No angina pectoris requiring nitrate therapy - No myocardial infarction within the past 6 months - No other significant cardiovascular disease Pulmonary - No pulmonary embolus within the past year - No ongoing hemoptysis Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study treatment - No preexisting thyroid abnormality in which normal thyroid function cannot be maintained by medication - No delayed wound healing, ulcers, or bone fractures - No uncontrolled psychiatric disorder - No other currently active* malignancy except nonmelanoma skin cancer NOTE: *Disease is not considered currently active if patient completed anticancer therapy and is considered to have < 30% risk of relapse PRIOR CONCURRENT THERAPY: Biologic therapy - No prior systemic immunotherapy for RCC - No prior thalidomide, anti-vascular endothelial growth factor (VEGF) therapy, VEGF receptor inhibitors, or antiangiogenic treatment of any kind - No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy - No prior systemic chemotherapy for RCC - No concurrent chemotherapy Endocrine therapy - No concurrent systemic corticosteroid therapy except the following: - Topical and inhaled steroids - Replacement therapy for adrenal insufficiency - No concurrent hormones except those administered for nondisease-related conditions (e.g., insulin for diabetes) Radiotherapy - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - Prior palliative radiotherapy to metastatic lesions allowed provided at least 1 measurable or nonmeasurable lesion remains untreated - No concurrent palliative radiotherapy Surgery - At least 4 weeks since prior major surgery and recovered Other - No other prior systemic investigational therapy for RCC - No other prior adjuvant or neoadjuvant systemic therapy for RCC - No concurrent full-dose oral or parenteral anticoagulation* NOTE: *Low-dose (1 mg) warfarin for maintenance of catheter patency and/or daily prophylactic aspirin is allowed


Study is Available At:


Original ID:

CALGB-90206


NCT ID:

NCT00072046


Secondary ID:

U10CA031946


Study Acronym:


Brief Title:

Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)


Official Title:

A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma


Overall Status:

Completed


Study Phase:

Phase 3


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Alliance for Clinical Trials in Oncology


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Randomized, Endpoint Classification: S


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

732


Enrollment Type:

Actual


Overall Contact Information

Official Name:Brian I. Rini, MD
Study Chair
University of California, San Francisco

Study Dates

Start Date:October 2003
Completion Date:November 2012
Completion Type:Actual
Primary Completion Date:January 2004
Primary Completion Type:Actual
Verification Date:June 2015
Last Changed Date:June 23, 2015
First Received Date:November 4, 2003

Study Outcomes

Outcome Type:Primary Outcome
Measure:Overall Survival
Time Frame:5 years
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Time to progression
Time Frame:q 3 cycles
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Toxicity
Time Frame:q cycle
Safety Issues:True

Study Interventions

Intervention Type:Biological
Name:bevacizumab
Description:10mg/kg IV infusion on Days 1 & 15 of each cycle
Arm Name:Interferon + bevacizumab
Intervention Type:Biological
Name:recombinant interferon alfa
Description:9 million units subQ injection 3 x/week for 4 weeks
Arm Name:Interferon

Study Arms

Study Arm Type:Experimental
Arm Name:Interferon
Description:Treatment with interferon alfa 2b
Study Arm Type:Experimental
Arm Name:Interferon + bevacizumab
Description:Addition of bevacizumab to interferon alfa 2b treatment

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Alliance for Clinical Trials in Oncology
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.
PMID:20368558
Reference Type:Results Reference
Citation:Rini BI, Halabi S, Rosenberg J, et al.: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. [Abstract] J Clin Oncol 27 (Suppl 15): A-LBA5019, 2009.
Reference Type:Results Reference
Citation:Rini BI, Halabi S, Rosenberg JE, et al.: CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-350, 2008.
Reference Type:Results Reference
Citation:Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20;26(33):5422-8. doi: 10.1200/JCO.2008.16.9847. Epub 2008 Oct 20.
PMID:18936475
Reference Type:Results Reference
Citation:Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15;10(8):2584-6.
PMID:15102658

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.